28/07/2015 11:24:17 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
07/27/20157:00AMBWEuropean Medicines Agency Validates & Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elo...
Results from two clinical trials (ELOQUENT-2 & CA204-009), each combining Empliciti with a different standard of care regimen included in the submission Empliciti is poised to be the first-in-class SLAMF7-directed immunostimulatory antibody Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced... More...>>
07/24/20152:06PMBWFDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3
Daklinza in combination with sofosbuvir is the first 12-week, all-oral therapy that offers SVR12 for the vast majority of genotype 3 patients Hepatitis C genotype 3 is one of the most difficult-to-treat genotypes Announcement marks the first approval of Daklinza in the United States Bristol-Myers Squibb Company (NYSE:BMY... More...>>
07/23/20151:35PMDJNBristol-Myers Revenue Boosted by Cancer Drug Opdivo
By Jonathan D. Rockoff and Tess Stynes Bristol-Myers Squibb Co. said Thursday its second-quarter revenue rose 7% thanks to a boost from sales of its new Opdivo cancer drug, results indicating the company's big bet on such immunotherapies is paying off. For years, researchers struggled to figure out how to enlist the body's... More...>>
07/23/20151:08PMDJNCorrection to Bristol-Myers Results Article
Bristol-Myers reported a loss of $130 million, or eight cents a share, compared with a year-earlier profit of $333 million, or 20 cents a share. "Bristol-Myers Results Lifted by Immunotherapy Drug Opdivo," at 7:36 a.m. ET, misstated the year-earlier figures. Subscribe to WSJ: http://online.wsj.com?mod=djnwires More...>>
07/23/20158:20AMDJNBristol-Myers Gets a Revenue Boost from Opdivo
Bristol-Myers Squibb Co. said its second-quarter revenue rose 7% with a boost from sales of its Opdivo immunotherapy drug and its hepatitis C franchise. Revenue increased to $4.2 billion from $3.89 billion a year earlier. Excluding currency effects, the growth was 16%. Analysts polled by Thomson Reuters expected revenue... More...>>
07/23/20158:06AMDJNBristol-Myers Results Lifted by Immunotherapy Drug Opdivo
By Tess Stynes Bristol-Myers Squibb Co. said its second-quarter revenue rose 7% with a boost from sales of its Opdivo immunotherapy drug and its hepatitis C franchise. Revenue increased to $4.2 billion from $3.89 billion a year earlier. Excluding currency effects, the growth was 16%. Analysts polled by Thomson Reuters... More...>>
07/23/20157:30AMBWBristol-Myers Squibb Reports Second Quarter Financial Results
Increases Revenues 7% to $4.2 Billion Posts Second Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.53 Achieves Important Regulatory and Clinical Milestones for Opdivo (nivolumab) Approvals in Europe for Metastatic Melanoma and Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Validation in Europe of Applications... More...>>
07/23/20156:30AMBWEuropean Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication i...
Variations include Opdivo in previously treated non-squamous, non-small cell lung cancer (NSCLC) and Opdivo in combination with Yervoy (ipilimumab) in advanced melanoma Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated two of the company’s type II variation... More...>>
07/21/20152:00PMBWSecond-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continue...
Investigational agent BMS-955176 represents a novel approach since it is designed to inhibit HIV-1 replication as compared to currently available treatments Bristol-Myers Squibb Company (NYSE:BMY) today announced additional Phase IIa proof-of-concept data for BMS-955176, a novel investigational agent designed to prevent... More...>>
07/21/201510:20AMDJNBristol-Myers Squibb Receives Breakthrough Designation for HIV Treatment
Bristol-Myers Squibb Co. said Tuesday that the U.S. Food and Drug Administration has granted breakthrough designation for its HIV treatment for users who have become accustomed to most other treatment options. Bristol's shares, which have increased 18% this year through Monday's close, jumped 5.2% in premarket trading... More...>>
07/21/201510:10AMDJNBristol-Myers Squibb Receives Breakthrough Designation for HIV Treatment
By Angela Chen Bristol-Myers Squibb Co. said Tuesday that the U.S. Food and Drug Administration has granted breakthrough designation for its HIV treatment for users who have become accustomed to most other treatment options. Bristol's shares, which have increased 18% this year through Monday's close, jumped 5.2% in premarket... More...>>
07/21/20159:00AMBWBristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for He...
BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes the need for new therapies for heavily treatment-experienced HIV-1 patients and may expedite the development and review of BMS-663068 Designation granted for investigational... More...>>
07/20/201512:07PMBWEuropean Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival fo...
First Immuno-Oncology agent approved in Europe for lung cancer, and the first major treatment advance in more than a decade Approval based on Checkmate -017, which showed nivolumab had a 41% reduction in the risk of death versus docetaxel, and demonstrated nearly doubled overall survival at one-year versus chemotherapy... More...>>
07/20/20159:25AMPRNUSWatch List for Drug Manufacturers - Major Equities -- Pfizer, Bristol-Myers Squibb, Eli Lilly, Kythera Biopharma, and Impax L...
Watch List for Drug Manufacturers - Major Equities -- Pfizer, Bristol-Myers Squibb, Eli Lilly, Kythera Biopharma, and Impax Laboratories PR Newswire NEW YORK, July 20, 2015 NEW YORK, July 20, 2015 /PRNewswire/ -- Equity Research Institute has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Bristol-Myers... More...>>
07/20/20158:00AMBWCheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early
Opdivo Demonstrates Superior Overall Survival Compared to Everolimus in Patients with Previously-Treated Advanced or Metastatic Renal Cell Carcinoma Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) versus everolimus in previously-treated... More...>>
07/16/20159:21AMBWEuropean Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir & cobicistat fixed-dose combination) for the Treatme...
The European Commission approval is based upon Phase III clinical trial - Reyataz®(atazanavir) and cobicistat combination demonstrated virologic failure rates as low as 6% at 48 weeks and 8% at 144 weeks [HIV-1 RNA ≥50 copies/mL: 6% Reyataz/cobicistat arm and 4% Reyataz/ritonavir arm at 48 weeks; 8% Reyataz/cobicistat... More...>>
07/15/20153:20PMDJNMead Johnson Stock Falls to New Low After Revised Earnings Outlook
Mead Johnson Nutrition Co. shares dived to a fresh 52-week low on Wednesday after the baby-formula maker slashed its full-year outlook, citing weak sales during its second quarter ended in June. The Chicago company released its earnings forecast after the closing bell on Tuesday, pushing shares as low as $83.50 on stronger... More...>>
07/15/20158:30AMBWMUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases
The Medical University of South Carolina and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered into a translational research collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis. The agreement includes studies designed to improve... More...>>
07/13/20155:30PMDJNRoche Says Drug Meets Bladder Cancer Target
An experimental Roche Holding AG drug, designed to unleash the body's immune system to fight cancer, shrank tumors in patients with advanced bladder cancer in a new clinical trial, the drug maker said Monday. Roche's Genentech unit, which developed the drug, atezolizumab, said it plans to discuss the results with health... More...>>
07/07/20156:43PMDJNChange in C-Suite: Why the Boss Is Younger Than You Are
By Joann S. Lublin And James R. Hagerty Generation X is moving into the corner office, bringing a different style to the way companies are run. As older baby boomers retire, more companies are turning to members of Gen X, those born between about 1965 and 1980, and younger boomers, now in their mid-50s. Among companies... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy150728 11:24